Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MOG-Abs) were first detected
by immunoblot and enzyme-linked immunosorbent assay nearly 30 years ago, but their …
by immunoblot and enzyme-linked immunosorbent assay nearly 30 years ago, but their …
B cells in autoimmune and neurodegenerative central nervous system diseases
B cells are essential components of the adaptive immune system and have important roles
in the pathogenesis of several central nervous system (CNS) diseases. Besides producing …
in the pathogenesis of several central nervous system (CNS) diseases. Besides producing …
[HTML][HTML] Trial of satralizumab in neuromyelitis optica spectrum disorder
T Yamamura, I Kleiter, K Fujihara… - … England Journal of …, 2019 - Mass Medical Soc
Background Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of
the central nervous system and is associated with autoantibodies to anti–aquaporin-4 …
the central nervous system and is associated with autoantibodies to anti–aquaporin-4 …
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
A Traboulsee, BM Greenberg, JL Bennett… - The Lancet …, 2020 - thelancet.com
Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised …
Background Azathioprine is used as a first-line treatment to prevent relapses of
neuromyelitis optica spectrum disorder (NMOSD). Tocilizumab has been reported to reduce …
neuromyelitis optica spectrum disorder (NMOSD). Tocilizumab has been reported to reduce …
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
AJ Thompson, BL Banwell, F Barkhof… - The Lancet …, 2018 - thelancet.com
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in
research and clinical practice. Scientific advances in the past 7 years suggest that they might …
research and clinical practice. Scientific advances in the past 7 years suggest that they might …
Astrocyte barriers to neurotoxic inflammation
MV Sofroniew - Nature Reviews Neuroscience, 2015 - nature.com
Astrocytes form borders (glia limitans) that separate neural from non-neural tissue along
perivascular spaces, meninges and tissue lesions in the CNS. Transgenic loss-of-function …
perivascular spaces, meninges and tissue lesions in the CNS. Transgenic loss-of-function …
Mechanisms of autoantibody-induced pathology
RJ Ludwig, K Vanhoorelbeke, F Leypoldt… - Frontiers in …, 2017 - frontiersin.org
Autoantibodies are frequently observed in healthy individuals. In a minority of these
individuals, they lead to manifestation of autoimmune diseases, such as rheumatoid arthritis …
individuals, they lead to manifestation of autoimmune diseases, such as rheumatoid arthritis …
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
K Fujihara, JL Bennett, J de Seze… - Neurology …, 2020 - AAN Enterprises
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder that
preferentially affects the spinal cord and optic nerve. Most patients with NMOSD experience …
preferentially affects the spinal cord and optic nerve. Most patients with NMOSD experience …
Neuromyelitis spectrum disorders
BG Weinshenker, DM Wingerchuk - Mayo Clinic Proceedings, 2017 - Elsevier
The understanding of neuromyelitis optica spectrum disorder (NMOSD) has evolved
substantially since its initial description over a century ago. The discovery in 2004 of a …
substantially since its initial description over a century ago. The discovery in 2004 of a …